DE3023111C2 - - Google Patents
Info
- Publication number
- DE3023111C2 DE3023111C2 DE3023111A DE3023111A DE3023111C2 DE 3023111 C2 DE3023111 C2 DE 3023111C2 DE 3023111 A DE3023111 A DE 3023111A DE 3023111 A DE3023111 A DE 3023111A DE 3023111 C2 DE3023111 C2 DE 3023111C2
- Authority
- DE
- Germany
- Prior art keywords
- cis
- lactate
- platinum
- c3h5o3
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 55
- 125000003745 glyceroyl group Chemical group C(C(O)CO)(=O)* 0.000 claims description 19
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 16
- 229910052697 platinum Inorganic materials 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 150000003893 lactate salts Chemical class 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 claims description 4
- 101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 150000003057 platinum Chemical class 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- -1 alkali metal lactate salts Chemical class 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 231100000816 toxic dose Toxicity 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 229910021607 Silver chloride Inorganic materials 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000002329 infrared spectrum Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 5
- 230000001476 alcoholic effect Effects 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- LMEWRZSPCQHBOB-UHFFFAOYSA-M silver;2-hydroxypropanoate Chemical compound [Ag+].CC(O)C([O-])=O LMEWRZSPCQHBOB-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000002211 ultraviolet spectrum Methods 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 150000001450 anions Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- CPBWHVPEXLELDF-UHFFFAOYSA-L 2-hydroxypropanoate;platinum(2+) Chemical compound [Pt+2].CC(O)C([O-])=O.CC(O)C([O-])=O CPBWHVPEXLELDF-UHFFFAOYSA-L 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000003058 platinum compounds Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- DYQHASUHNNRLRA-UHFFFAOYSA-L C(C(O)C)(=O)[O-].[Pt+2].C(CN)N.C(C(O)C)(=O)[O-] Chemical compound C(C(O)C)(=O)[O-].[Pt+2].C(CN)N.C(C(O)C)(=O)[O-] DYQHASUHNNRLRA-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ZYZCZCHRQQZTHI-UHFFFAOYSA-N cyclohexane-1,1-diamine;platinum Chemical compound [Pt].NC1(N)CCCCC1 ZYZCZCHRQQZTHI-UHFFFAOYSA-N 0.000 description 1
- POQBJIOLWPDPJE-UHFFFAOYSA-N cyclohexane-1,2-diamine;platinum Chemical compound [Pt].NC1CCCCC1N POQBJIOLWPDPJE-UHFFFAOYSA-N 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 125000003916 ethylene diamine group Chemical group 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 231100001225 mammalian toxicity Toxicity 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910001510 metal chloride Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- PHZLMBHDXVLRIX-UHFFFAOYSA-M potassium lactate Chemical compound [K+].CC(O)C([O-])=O PHZLMBHDXVLRIX-UHFFFAOYSA-M 0.000 description 1
- 239000001521 potassium lactate Substances 0.000 description 1
- 235000011085 potassium lactate Nutrition 0.000 description 1
- 229960001304 potassium lactate Drugs 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 229940071536 silver acetate Drugs 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/050,235 US4271085A (en) | 1979-06-20 | 1979-06-20 | Cis-platinum (II) amine lactate complexes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3023111A1 DE3023111A1 (de) | 1981-01-08 |
| DE3023111C2 true DE3023111C2 (US07829113-20101109-C00009.png) | 1988-09-22 |
Family
ID=21964121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19803023111 Granted DE3023111A1 (de) | 1979-06-20 | 1980-06-20 | Platinkomplex und seine verwendung |
Country Status (8)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5716895A (en) * | 1980-07-05 | 1982-01-28 | Otsuka Chem Co Ltd | Platinum 2 complex and antitumor agent containing the same as active principle |
| JPS57123198A (en) * | 1981-01-23 | 1982-07-31 | Shionogi & Co Ltd | Novel platinum complex |
| JPS59112995A (ja) * | 1982-12-21 | 1984-06-29 | Shionogi & Co Ltd | 新規グリコ−ル酸白金錯体 |
| US4598091A (en) * | 1983-02-18 | 1986-07-01 | Degussa Aktiengesellschaft | (1,2-diphenyl)-ethylenediamine)-platinum (II) complex compounds |
| AU558747B2 (en) * | 1983-05-10 | 1987-02-05 | Andrulis Research Corporation | Bis-platinum complexes as antitumor agents |
| US4565884A (en) * | 1983-05-10 | 1986-01-21 | Andrulis Research Corporation | Bis-platinum complexes as antitumor agents |
| US4720504A (en) * | 1983-05-10 | 1988-01-19 | Andrulis Research Corporation | Use of bis-platinum complexes as antitumor agents |
| JPS59222498A (ja) * | 1983-06-01 | 1984-12-14 | Shionogi & Co Ltd | 新規グリコ−ル酸系白金錯体および抗悪性腫瘍剤 |
| US4562275A (en) * | 1984-03-23 | 1985-12-31 | Bristol-Myers Co. | Antitumor platinum complexes |
| JPS617283A (ja) * | 1984-06-20 | 1986-01-13 | Shionogi & Co Ltd | 新規白金錯体および抗悪性腫瘍剤 |
| US5384127A (en) * | 1985-10-18 | 1995-01-24 | Board Of Regents, The University Of Texas System | Stable liposomal formulations of lipophilic platinum compounds |
| US5041581A (en) * | 1985-10-18 | 1991-08-20 | The University Of Texas System Board Of Regents | Hydrophobic cis-platinum complexes efficiently incorporated into liposomes |
| US5117022A (en) * | 1985-10-18 | 1992-05-26 | The Board Of Regents, The University Of Texas System | Hydrophobic cis-platinum complexes efficiently incorporated into liposomes |
| US5393909A (en) * | 1988-11-22 | 1995-02-28 | Board Of Regents, The University Of Texas System | Diamine platinum complexes as antitumor agents |
| US5041578A (en) * | 1988-11-22 | 1991-08-20 | Board Of Regents, The University Of Texas System | Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents |
| US5434256A (en) * | 1988-11-22 | 1995-07-18 | Board Of Regents, The University Of Texas System | Diamine platinum complexes as antitumor agents |
| US5130450A (en) * | 1990-04-25 | 1992-07-14 | Nippon Kayaku Kabushiki Kaisha | Platinum complexes |
| AU775373B2 (en) | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| US7138520B2 (en) * | 2003-01-13 | 2006-11-21 | Massachusetts Institute Of Technology | Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH605550A5 (US07829113-20101109-C00009.png) * | 1972-06-08 | 1978-09-29 | Research Corp | |
| JPS535369A (en) * | 1976-07-02 | 1978-01-18 | Fuji Iron Works | Goods selecting apparatus in wind changing machine |
| US4115418A (en) * | 1976-09-02 | 1978-09-19 | Government Of The United States Of America | 1,2-diaminocyclohexane platinum (ii) complexes having antineoplastic activity |
| JPS5829957B2 (ja) * | 1977-09-12 | 1983-06-25 | 喜徳 喜谷 | 新規な白金錯体 |
-
1979
- 1979-06-20 US US06/050,235 patent/US4271085A/en not_active Expired - Lifetime
-
1980
- 1980-06-12 CA CA000353897A patent/CA1134378A/en not_active Expired
- 1980-06-14 JP JP7963080A patent/JPS5645495A/ja active Granted
- 1980-06-18 AU AU59368/80A patent/AU537574B2/en not_active Ceased
- 1980-06-18 FR FR8013507A patent/FR2459246A1/fr active Granted
- 1980-06-18 IT IT49001/80A patent/IT1149202B/it active
- 1980-06-18 GB GB8019975A patent/GB2053212B/en not_active Expired
- 1980-06-20 DE DE19803023111 patent/DE3023111A1/de active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| US4271085A (en) | 1981-06-02 |
| JPS5645495A (en) | 1981-04-25 |
| AU5936880A (en) | 1981-01-08 |
| GB2053212A (en) | 1981-02-04 |
| AU537574B2 (en) | 1984-07-05 |
| IT1149202B (it) | 1986-12-03 |
| DE3023111A1 (de) | 1981-01-08 |
| IT8049001A0 (it) | 1980-06-18 |
| CA1134378A (en) | 1982-10-26 |
| GB2053212B (en) | 1983-06-22 |
| FR2459246B1 (US07829113-20101109-C00009.png) | 1984-11-23 |
| JPH036156B2 (US07829113-20101109-C00009.png) | 1991-01-29 |
| FR2459246A1 (fr) | 1981-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3023111C2 (US07829113-20101109-C00009.png) | ||
| DE3586759T2 (de) | Antitumor-platin-komplexe. | |
| US4115418A (en) | 1,2-diaminocyclohexane platinum (ii) complexes having antineoplastic activity | |
| DE2845371A1 (de) | Platinkomplexverbindung, pharmazeutische stoffzusammensetzung mit einer solchen verbindung und deren anwendung | |
| DE8817132U1 (de) | 1,2-Bis(aminomethyl)cyclobutan-Platin-Komplexe | |
| DE2845372C2 (US07829113-20101109-C00009.png) | ||
| DE3117216A1 (de) | Organoplatinkomplexe und ihre verwendung bei der bekaempfung von tumoren | |
| DE3152175C2 (US07829113-20101109-C00009.png) | ||
| EP1561754B1 (de) | Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen | |
| DE2845373A1 (de) | Platin-verbindung und verfahren zu ihrer herstellung sowie anwendung der verbindung | |
| DE3008662C2 (US07829113-20101109-C00009.png) | ||
| DE3406161A1 (de) | Verfahren zur darstellung von platin(ii)-komplexen | |
| AT390610B (de) | Verfahren zur herstellung von neuen platin-(ii) -diaminkomplexen | |
| US4902797A (en) | Ammine-alicyclic amine-platinum complexes and antitumor agents | |
| DE3630497A1 (de) | Cis-platin-komplexe, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische mittel | |
| DE3438440A1 (de) | Platin-diamin-komplex | |
| DE69422712T2 (de) | Tris-platin-komplexe | |
| DE69813903T2 (de) | Antikrebs-platin-(vi)-komplexe zur oralen verabreichung | |
| DE3022957C2 (US07829113-20101109-C00009.png) | ||
| US4457926A (en) | Cis-Platinum(II) amine ascorbate complexes | |
| DE69521810T2 (de) | Dreikernige kationische platinkomplexe mit antitumor wirkung, und diese enthaltende arzneizusammensetzungen | |
| CH665421A5 (de) | Gemischte karboxylatokomplexe von platin (ii) und verfahren zu ihrer herstellung. | |
| US4758588A (en) | Diaminocyclohexane platinum complexes | |
| DE69028844T2 (de) | Neuer platin(ii)komplex und mittel für die behandlung von bösartigen tumoren | |
| WO2004099224A1 (de) | Carboplatin-artige platin (ii)- komplexe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |